Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

BACKGROUND: SDZ-ADL (GP2017; Sandoz GmbH, Austria) is an EMA-/FDA-approved adalimumab biosimilar. The effect of SDZ-ADL on quality of life (QoL) and patient-reported outcomes (PROs) was assessed as part of two phase III studies, one in patients with moderate‐to‐severe chronic plaque psoriasis (PsO;...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Leonardi, Craig L., Gaylis, Norman, Jauch-Lembach, Julia, Balfour, Alison, Lemke, Lena, Hachaichi, Sohaib, Brueckmann, Ines, Festini, Teodora, Wiland, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952364/
https://www.ncbi.nlm.nih.gov/pubmed/33651341
http://dx.doi.org/10.1007/s40259-021-00470-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952364/
https://www.ncbi.nlm.nih.gov/pubmed/33651341
http://dx.doi.org/10.1007/s40259-021-00470-1

Ejemplares similares